CoChat

Obesity diminishes response to PD-1-based immunotherapies in renal cancer

Open access
Boi, Shannon K, Orlandella, Rachael M, Gibson, Justin Tyler, Turbitt, William James, Wald, Gal, Thomas, Lewis, Buchta Rosean, Claire, Norris, Katlyn E, Bing, Megan, Bertrand, Laura, Gross, Brett P, Makkouk, Amani, Starenki, Dmytro, Farag, Kristine I, Sorge, Robert E, Brown, James A, Gordetsky, Jennifer, Yasin, Hesham, Garje, Rohan, Nandagopal, Lakshminarayanan, Weiner, George J, Lubaroff, David M, Arend, Rebecca C, Li, Peng, Zakharia, Yousef, Yang, Eddy, Salem, Aliasger K, Nepple, Kenneth, Marquez-Lago, Tatiana T, Norian, Lyse A · 2020 · Journal for ImmunoTherapy of Cancer
Cited by 94

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: Obesity is a major risk factor for renal cancer, yet our understanding of its effects on antitumor immunity and immunotherapy outcomes remains incomplete. Deciphering these associations is critical, given the growing clinical use of immune checkpoint inhibitors for metastatic disease and mounting evidence for an obesity paradox in the context of cancer immunotherapies, wherein obese patients with cancer have improved outcomes. Methods: We investigated associations between host obesity and anti-programmed cell death (PD-1)-based outcomes in both renal cell carcinoma (RCC) subjects and orthotopic murine renal tumors. Overall survival (OS) and progression-free survival (PFS) were determined for advanced RCC subjects receiving standard of care anti-PD-1 who had ≥6 months of follow-up from treatment initiation (n=73). Renal tumor tissues were collected from treatment-naive subjects categorized as obese (body mass index, ‘BMI’ ≥30 kg/m 2) or non-obese (BMI <30 kg/m 2) undergoing partial or full nephrectomy (n=19) then used to evaluate the frequency and phenotype of intratumoral CD8+ T cells, including PD-1 status, by flow cytometry. In mice, antitumor immunity and excised renal tumor weights were evaluated ±administration of a combinatorial anti-PD-1 therapy. For a subset of murine renal tumors, immunophenotyping was performed by flow cytometry and immunogenetic profiles were evaluated via nanoString. Results: With obesity, RCC patients receiving anti-PD-1 administration exhibited shorter PFS (p=0.0448) and OS (p=0.0288). Treatment-naive renal cancer subjects had decreased frequencies of tumor-infiltrating PD-1 high CD8+ T cells, a finding recapitulated in our murine model. Following anti-PD-1-based immunotherapy, both lean and obese mice possessed distinct populations of treatment responders versus non-responders; however, obesity reduced the frequency of treatment responders (73% lean vs 44% obese). Tumors from lean and obese treatment responders displayed similar immunogenetic profiles, robust infiltration by PD-1 int interferon (IFN)γ+CD8+ T cells and reduced myeloid-derived suppressor cells (MDSC), yielding favorable CD44+CD8+ T cell to MDSC ratios. Neutralizing interleukin (IL)-1β in obese mice improved treatment response rates to 58% and reduced MDSC accumulation in tumors. Conclusions: We find that obesity is associated with diminished efficacy of anti-PD-1-based therapies in renal cancer, due in part to increased inflammatory IL-1β levels, highlighting the need for continued study of this critical issue.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-000725

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 94

Metadata

Authors
Boi, S. K., Orlandella, R. M., Gibson, J. T., Turbitt, W. J., Wald, G., Thomas, L., Buchta Rosean, C., Norris, K. E., Bing, M., Bertrand, L., Gross, B. P., Makkouk, A., Starenki, D., Farag, K. I., Sorge, R. E., Brown, J. A., Gordetsky, J., Yasin, H., Garje, R., Nandagopal, L., Weiner, G. J., Lubaroff, D. M., Arend, R. C., Li, P., Zakharia, Y., Yang, E., Salem, A. K., Nepple, K., Marquez-Lago, T. T., & Norian, L. A.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-12
Volume
8
Issue
2
Pages
e000725
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3115193457
Cited by
94
References
14
FWCI
3.93
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Obesity diminishes response to PD-1-based immunotherapies in renal cancer. https://app.cochat.ai/papers/10.1136/jitc-2020-000725
The paper
Boi, S. K., Orlandella, R. M., Gibson, J. T., Turbitt, W. J., Wald, G., Thomas, L., Buchta Rosean, C., Norris, K. E., Bing, M., Bertrand, L., Gross, B. P., Makkouk, A., Starenki, D., Farag, K. I., Sorge, R. E., Brown, J. A., Gordetsky, J., Yasin, H., Garje, R., . . . Norian, L. A. (2020). Obesity diminishes response to PD-1-based immunotherapies in renal cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000725

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.